1. 1. Birkeland, K. I., Home, P. D., Wendisch, U., Ratner, R. E., Johansen, T., Endahl, L. A., Lyby, K., Jendle, J. H., Roberts, A. P., DeVries, J. H. and Meneghini, L. F. 2011. Insulin degludec in type 1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine. Diabetes Care 34: 661–665.
2. 2. Feldman, E. C., Nelson, R. W., Reusch, C. and Scoot-Moncrieff, J. C. 2015. Feline diabetes mellitus. pp. 258–314. In: Canine and Feline Endocrinology, 4th ed., Saunders, Philadelphia.
3. 3. Haahr, H. and Heise, T. 2014. A review of the pharmacological properties of insulin degludec and their clinical relevance. Clin. Pharmacokinet. 53: 787–800.
4. 4. Jonassen, I., Havelund, S., Hoeg-Jensen, T., Steensgaard, D. B., Wahlund, P. O. and Ribel, U. 2012. Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin. Pharm. Res. 29: 2104–2114.
5. 5. Kurtzhals, P., Heise, T., Strauss, H., Bottcher, S., Granhall, C., Haahr, H. and Jonassen, I. 2011. Multi-hexamer formation is the underlying basis for the ultra-long glucose-lowering effect of insulin degludec. Diabetologia 54: S426.